Lupin gets FDA nod for generic Kerydin

The Food and Drug Administration has given its blessing to Lupin for tavaborole topical solution, 5%, an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

The product is the generic of Anacor’s Kerydin.

Lupin's generic will be manufactured at Lupin’s facility in Pithampur, India.

Tavaborole topical solution had a market value of roughly $76 million, according to IQVIA December 2020 data.